New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
11:32 EDTILMN, SQNM, PKI, LHLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.
News For LH;SQNM;ILMN;PKI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
05:42 EDTILMNIllumina and Genomics England enters bioinformatics partnership
Illumina and Genomics England announced a partnership to develop a platform and knowledge base that can be used to improve and automate genome interpretation. The tools will aim to operate within the Genomics England secure database to enable researchers and clinicians to access information and reports more readily. Genomics England is partnering with Illumina to develop and deliver systems for clinical interpretation, decision support and knowledge curation for the 100,000 Genomes Project. This non-exclusive partnership with Illumina will run in parallel with the other clinical interpretation and bioinformatics providers involved in the 100,000 Genomes Project. Illumina and Genomics England will collaborate to develop a set of informatics tools, which will support the delivery of genomic clinical and research services at a population scale to the NHS Genomic Medicine Centers and the Genomics England Clinical Interpretation Partners. All of the tools will include open application programming interfaces so that other bioinformatics solution partners can continue to provide services within the Project. Under the terms of the partnership, Illumina will develop interpretation and reporting tools for the purpose of delivering reports on all genomes that are sequenced through the 100,000 Genomes Project. Genomics England will provide access to whole genome sequence and de-identified phenotypic data for the development of this suite of tools for personalised medicine. The tools will be used to curate and manage the knowledge base of information generated over the course of the project with a focus on rare disease and common cancers. Illumina and Genomics England have agreed to make available the clinical findings arising from the 100,000 Genomes Project to approved users of the tools developed through the collaboration.
February 9, 2016
11:09 EDTILMNIllumina reportedly bought ThromboDx last month, says Piper Jaffray
Subscribe for More Information
February 8, 2016
08:34 EDTPKIPerkinElmer selloff a buying opportunity, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier recommends investors buy PerkinElmer following the recent pullback in shares. The stock is down 18% over the last month and is now one of the most attractively valued tools companies, Brokmeier tells investors in a research note. He keeps a Buy rating on the name with a $59 price target.
08:21 EDTPKIPerkinElmer weakness creates buying opportunity, says Cantor
Subscribe for More Information
February 4, 2016
16:30 EDTPKIPerkinElmer sees FY16 adjusted EPS $2.65-$2.75, consensus $2.82
Subscribe for More Information
16:29 EDTPKIPerkinElmer reports Q4 adjusted EPS 86c, consensus 87c
Reports Q4 revenue $608.1M, consensus $617.52M.
06:23 EDTILMNIllumina downgraded to Hold from Buy at Canaccord
Subscribe for More Information
February 3, 2016
10:02 EDTILMNIllumina falls sharply after results
The company's report last night after the close disappointed investors, with shares currently down over 6.5% to $144.30. At that price next support is at $139.16. Resistance is at $146.56.
09:19 EDTILMNOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Boot Barn (BOOT), up 20.7%... Oclaro (OCLR), up 8.2%... Edwards Lifesciences (EW), up 5.8%... Natural Health (NHTC), up 5.7%... Viavi Solutions (VIAV), up 2.8%. ALSO HIGHER: Conatus (CNAT), up 18.8% after the FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis... Marvell Technology (MRVL), up 3.3% after Starboard Value disclosed a 6.7% activist stake in the company... Syngenta (SYT), up 2.9% after ChemChina offers to acquire the company in a transaction valued over $43B. DOWN AFTER EARNINGS: Navios Maritime Partners (NMM), down 33.5%... National-Oilwell Varco (NOV), down 7.9%... Chipotle (CMG), down 5.7%... Yahoo (YHOO), down 1.9%... Mondelez (MDLZ), down 4.4%... Illumina (ILMN), down 4.6%... Alexion Pharmaceuticals (ALXN), down 3.5%... Merck (MRK), down fractionally.
February 2, 2016
16:34 EDTILMNIllumina sees FY16 EPS $3.55-$3.65, consensus $3.64
Subscribe for More Information
16:34 EDTILMNIllumina reports Q4 EPS 81c, consensus 82c
Reports Q4 revenue $591.5M, consensus $585.18M.
14:32 EDTILMNNotable companies reporting after market close
Subscribe for More Information
13:11 EDTILMNIllumina technical comments ahead of earnings
Subscribe for More Information
February 1, 2016
15:21 EDTILMNIllumina volatility elevated into Q4 and outlook
Illumina February weekly call option implied volatility is at 84, February is at 54, March is at 45; compared to its 52-week range of 22 to 64, suggesting large near term price movement into the expected release of Q4 results on February 2.
06:33 EDTILMNIllumina signs four biobanking deals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use